Sunshine Biopharma (SBFM) Receivables (2015 - 2026)

Sunshine Biopharma's Receivables history runs 11 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• Quarterly Receivables rose 16.44% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 16.44% YoY) and the FY2025 annual result came in at $3.5 million, down 10.56% from the prior year.
• Receivables was $4.0 million for Q1 2026 at Sunshine Biopharma, up from $3.5 million in the prior quarter.
• Across five years, Receivables topped out at $4.2 million in Q3 2025 and bottomed at $22.0 in Q3 2022.
• A 5-year average of $2.5 million and a median of $2.8 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables plunged 98.05% — and 2023, when it jumped 9245895.45%.
• Sunshine Biopharma's Receivables stood at $1.9 million in 2022, then soared by 33.48% to $2.6 million in 2023, then surged by 51.56% to $3.9 million in 2024, then retreated by 10.56% to $3.5 million in 2025, then gained by 15.95% to $4.0 million in 2026.
• Business Quant data shows SBFM's Receivables at $4.0 million in Q1 2026, $3.5 million in Q4 2025, and $4.2 million in Q3 2025.